M Reis

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. doi request reprint Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data
    M Reis
    Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linkoping, Sweden
    Psychol Med 40:1723-33. 2010
  2. doi request reprint Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database
    Margareta Reis
    Department of Forensic Chemistry and Genetics, Swedish National Board of Forensic Medicine, Linkoping, Sweden
    Ther Drug Monit 31:42-56. 2009
  3. ncbi request reprint Therapeutic drug monitoring of escitalopram in an outpatient setting
    Margareta Reis
    Department of Clinical Pharmacology, Faculty of Health Sciences, Linkoping University Hospital, Linkoping, Sweden
    Ther Drug Monit 29:758-66. 2007
  4. ncbi request reprint [Stereochemistry and drug effects--a neglected field of knowledge]
    Margareta Reis
    Avdelningen för klinisk farmakologi, Hälsouniversitetet, Linkoping
    Lakartidningen 103:1305-6, 1309-11. 2006
  5. ncbi request reprint Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study
    Margareta Reis
    Department of Medicine and Care, Division of Clinical Pharmacology, Linkoping University, Linkoping, Sweden
    Ther Drug Monit 27:469-77. 2005
  6. ncbi request reprint Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997
    Margareta Reis
    Division of Psychiatry, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linkoping, Sweden
    Ther Drug Monit 25:183-91. 2003
  7. ncbi request reprint Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting
    Margareta Reis
    Department of Psychiatry, Linkoping University, Linkoping, Sweden
    Ther Drug Monit 24:545-53. 2002
  8. ncbi request reprint Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression
    Margareta Reis
    Department of Medicine and Care, Division of Clinical Pharmacology, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Hum Psychopharmacol 19:283-91. 2004
  9. ncbi request reprint Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting
    Margareta Reis
    Division of Psychiatry, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    J Clin Psychopharmacol 22:406-13. 2002
  10. ncbi request reprint Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting
    Elisabeth Skogh
    Division of Psychiatry, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Ther Drug Monit 24:518-26. 2002

Detail Information

Publications14

  1. doi request reprint Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data
    M Reis
    Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linkoping, Sweden
    Psychol Med 40:1723-33. 2010
    ..Concerns have been expressed about possible adverse effects of the use of antidepressant medication during pregnancy, including risk for neonatal pathology and the presence of congenital malformations...
  2. doi request reprint Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database
    Margareta Reis
    Department of Forensic Chemistry and Genetics, Swedish National Board of Forensic Medicine, Linkoping, Sweden
    Ther Drug Monit 31:42-56. 2009
    ..By presenting a comprehensive compilation of therapeutic drug monitoring data for each drug, a reference tool is created, in addition to improved pharmacokinetic knowledge of antidepressant drugs...
  3. ncbi request reprint Therapeutic drug monitoring of escitalopram in an outpatient setting
    Margareta Reis
    Department of Clinical Pharmacology, Faculty of Health Sciences, Linkoping University Hospital, Linkoping, Sweden
    Ther Drug Monit 29:758-66. 2007
    ..However, women taking oral contraceptives showed a lower metabolic ratio compared with age-matched women. As a result of the wide range of the ratio in this population, these findings are not considered of clinical relevance...
  4. ncbi request reprint [Stereochemistry and drug effects--a neglected field of knowledge]
    Margareta Reis
    Avdelningen för klinisk farmakologi, Hälsouniversitetet, Linkoping
    Lakartidningen 103:1305-6, 1309-11. 2006
  5. ncbi request reprint Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study
    Margareta Reis
    Department of Medicine and Care, Division of Clinical Pharmacology, Linkoping University, Linkoping, Sweden
    Ther Drug Monit 27:469-77. 2005
    ..To help clinicians improve their treatment of patients with major depressive disorder, the possible implications on the PK with a long-term treatment are important to study...
  6. ncbi request reprint Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997
    Margareta Reis
    Division of Psychiatry, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linkoping, Sweden
    Ther Drug Monit 25:183-91. 2003
    ..Thus, this tendency of changes in the CIT disposition when multiple drugs are used (and multiple diseases are prevailing?) seems more general in character than specific for a certain drug or type of drugs...
  7. ncbi request reprint Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting
    Margareta Reis
    Department of Psychiatry, Linkoping University, Linkoping, Sweden
    Ther Drug Monit 24:545-53. 2002
    ..A number of polycombinations of drugs were assessed for interaction screening, and a trend for lowered ODV/VEN ratio was found, predominantly with concomitant medication with CNS-active drug(s) known to inhibit CYP2D6...
  8. ncbi request reprint Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression
    Margareta Reis
    Department of Medicine and Care, Division of Clinical Pharmacology, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Hum Psychopharmacol 19:283-91. 2004
    ..For the future, continuous efforts are warranted to perform PK investigations in the natural clinical setting in which the drugs are usually prescribed...
  9. ncbi request reprint Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting
    Margareta Reis
    Division of Psychiatry, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    J Clin Psychopharmacol 22:406-13. 2002
    ..64). In summary, the present study tentatively supports influences of sex, oral contraceptives, and smoking habits on the disposition of CIT in younger patients. Hence, future studies on CIT should assess these parameters...
  10. ncbi request reprint Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting
    Elisabeth Skogh
    Division of Psychiatry, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Ther Drug Monit 24:518-26. 2002
    ..The present TDM-based follow-up suggests that the influence of gender, smoking habits, and certain drug interactions may need to be considered for optimal dosage of OLA. TDM may be used for this purpose more readily in the future...
  11. ncbi request reprint Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels
    M Reis
    Department of Clinical Pharmacology, Linkoping University, Sweden
    J Anal Toxicol 31:254-64. 2007
    ..In addition to providing reference levels for each drug, the results may also be used to assess risk of toxicity and supply supplementary information to the standard fatal toxicity index...
  12. ncbi request reprint Serum concentrations of fluoxetine in the clinical treatment setting
    J Lundmark
    Department of Neuroscience and Locomotion, Linkoping University Hospital, Sweden
    Ther Drug Monit 23:139-47. 2001
    ..Moreover, the results of this study support the usefulness of a fluoxetine TDM procedure for individual dose optimization, detection of drug interactions, and assessments of patient compliance...
  13. ncbi request reprint Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations
    Margareta Reis
    Division of Clinical Pharmacology, Linkoping University, Linkoping, Sweden
    J Affect Disord 82:443-6. 2004
    ..A recent estimation in a psychiatric cohort showed numbers of noncompliance between 10% and 60%. Therapeutic drug monitoring (TDM) is one method assessing compliance by analysis of drug concentration in the blood...
  14. doi request reprint Therapeutic drug monitoring of ziprasidone in a clinical treatment setting
    Maria D Cherma
    Department of Clinical Pharmacology, Faculty of Health Sciences, Linkoping University Hospital, Sweden
    Ther Drug Monit 30:682-8. 2008
    ..In summary, great interindividual and intraindividual differences in ZIPconcentrations were observed. TDM of ZIP maybe used for individual dose adjustments and monitoring medication adherence...